Amryt Pharma plc (AMYT) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Amryt Pharma plc (AMYT) Healthcare & Pipeline Overview

Amryt Pharma plc, a commercial-stage biopharmaceutical company based in Ireland, specializes in acquiring, developing, and commercializing treatments for rare and orphan diseases. With a focus on unmet medical needs, Amryt markets therapies for conditions like lipodystrophy and Epidermolysis Bullosa, primarily in the Americas, Europe, and the Middle East.

What Is the Investment Thesis for AMYT?

Amryt Pharma plc presents an investment opportunity focused on the rare and orphan disease market. The company's existing portfolio of commercialized products, including metreleptin and lomitapide, generates revenue and provides a foundation for growth. Key value drivers include the successful development and commercialization of Oleogel-S10 for Epidermolysis Bullosa, a significant unmet need. The company's gross margin of 52.3% indicates potential for profitability as revenue scales. However, the negative profit margin of -8.2% highlights the need for improved cost management. Upcoming catalysts include clinical trial results for AP103 and potential regulatory approvals for Oleogel-S10. Potential risks include competition from other pharmaceutical companies and challenges in securing regulatory approvals.

Based on FMP financials and quantitative analysis

AMYT Key Highlights

• Gross Margin of 52.3% indicates strong pricing power and efficient cost of goods sold management.
• Negative Profit Margin of -8.2% suggests areas for improvement in operational efficiency and cost control.
• Beta of 0.76 indicates lower volatility compared to the overall market, potentially offering stability in a portfolio.
• Focus on rare and orphan diseases provides a niche market with less competition and potential for premium pricing.
• Commercial-stage biopharmaceutical company with existing revenue streams from metreleptin, oral octreotide, and lomitapide.

Who Are AMYT's Competitors?

AMYT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AMYT's Key Strengths?

• Specialized focus on rare and orphan diseases.
• Commercial-stage company with existing revenue streams.
• Proprietary products and intellectual property.
• Experienced management team.

What Are AMYT's Weaknesses?

• Negative profit margin.
• Reliance on a limited number of products.
• High research and development expenses.
• Regulatory risks associated with drug development.

What Could Drive AMYT Stock Higher?

• Potential regulatory approval and commercial launch of Oleogel-S10 for Epidermolysis Bullosa in the next 1-2 years.
• Clinical trial results for AP103 gene therapy for dystrophic EB.
• Continued revenue growth from existing products, including metreleptin, oral octreotide, and lomitapide.
• Strategic acquisitions of complementary assets and products.
• Geographic expansion into new markets, particularly in Asia-Pacific.

What Are the Key Risks for AMYT?

• Negative return on equity (-9.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from other pharmaceutical companies developing treatments for rare diseases.
• Patent expirations and generic competition for existing products.
• Pricing pressures from payers and government regulations.
• Regulatory risks associated with drug development and approval.
• Currency risk due to fluctuations in the exchange rate between the U.S. dollar and the Euro.

What Are the Growth Opportunities for AMYT?

• Oleogel-S10 Commercialization: Oleogel-S10 represents a significant growth opportunity for Amryt, targeting the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB). The EB market is underserved, and positive clinical trial results could lead to rapid adoption and revenue growth. Regulatory approval timelines suggest potential launch within the next 1-2 years.
• AP103 Gene Therapy Development: The development of AP103, a pre-clinical gene therapy for dystrophic EB, offers a long-term growth opportunity for Amryt. Gene therapy holds the promise of addressing the underlying genetic cause of EB, potentially providing a more effective treatment option. While still in the early stages of development, successful clinical trials could lead to a transformative therapy and significant market share. The timeline for commercialization is likely several years, but the potential impact is substantial.
• Geographic Expansion: Amryt currently sells its products in the Americas, Europe, and the Middle East. Expanding into new geographic markets, particularly in Asia-Pacific, represents a growth opportunity. These regions have a growing demand for rare disease treatments, driven by increasing healthcare spending and awareness. Market entry strategies could include partnerships with local distributors or establishing a direct commercial presence. The timeline for geographic expansion depends on regulatory approvals and market access considerations.
• Acquisition of Complementary Assets: Amryt has a history of acquiring complementary assets and products. Continuing to pursue strategic acquisitions of other companies or products focused on rare diseases could accelerate growth and expand the company's portfolio. Potential targets could include companies with complementary therapeutic areas, technologies, or geographic presence. The timeline for acquisitions is opportunistic and depends on market conditions and available targets.
• Lifecycle Management of Existing Products: Amryt can extend the lifecycle of its existing products through various strategies, such as developing new formulations, indications, or delivery methods. This can help to maintain market share and revenue streams in the face of competition. For example, exploring new indications for metreleptin or oral octreotide could unlock additional value. The timeline for lifecycle management initiatives is ongoing and depends on the specific product and market dynamics.

What Opportunities Does AMYT Have?

• Commercialization of Oleogel-S10 for Epidermolysis Bullosa.
• Development of AP103 gene therapy.
• Geographic expansion into new markets.
• Strategic acquisitions of complementary assets.

What Threats Does AMYT Face?

• Competition from other pharmaceutical companies.
• Patent expirations and generic competition.
• Pricing pressures from payers.
• Unfavorable regulatory changes.

What Are AMYT's Competitive Advantages?

• Focus on rare and orphan diseases creates a niche market with less competition.
• Proprietary products and intellectual property protection provide a competitive advantage.
• Established relationships with key opinion leaders and patient advocacy groups enhance market access.
• Specialized expertise in developing and commercializing treatments for rare diseases.

What Does AMYT Do?

Founded in 2015 and headquartered in Dublin, Ireland, Amryt Pharma plc is a biopharmaceutical company dedicated to improving the lives of patients with rare and orphan diseases. The company focuses on acquiring, developing, and commercializing specialized treatments that address significant unmet medical needs. Amryt's portfolio includes metreleptin, used as an adjunct to diet for treating complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. They also offer oral octreotide, a long-term maintenance therapy for acromegaly patients, and lomitapide, used alongside a low-fat diet and other lipid-lowering medications for adults with Homozygous familial Hypercholesterolaemia. Furthermore, Amryt is developing Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare genetic skin disorder, and AP103, a pre-clinical gene therapy for patients with dystrophic EB. Amryt sells its products across the Americas, Europe, and the Middle East, demonstrating a global reach in addressing rare disease treatments.

What Products and Services Does AMYT Offer?

• Develops and commercializes treatments for rare and orphan diseases.
• Provides metreleptin for treating complications of leptin deficiency.
• Offers oral octreotide for long-term maintenance therapy in acromegaly patients.
• Markets lomitapide for adults with Homozygous familial Hypercholesterolaemia.
• Develops Oleogel-S10 for the cutaneous manifestations of Epidermolysis Bullosa (EB).
• Is working on AP103, a pre-clinical gene therapy for patients with dystrophic EB.
• Sells products in the Americas, Europe, and the Middle East.

How Does AMYT Make Money?

• Develops and acquires treatments for rare and orphan diseases.
• Commercializes these treatments through its own sales force and distribution network.
• Generates revenue from the sale of its products, including metreleptin, oral octreotide, and lomitapide.

What Industry Does AMYT Operate In?

Amryt Pharma plc operates within the specialty and generic drug manufacturing industry, which is characterized by intense competition and regulatory scrutiny. The market for rare and orphan diseases is growing, driven by increased awareness, advancements in diagnostics, and regulatory incentives for developing treatments for these conditions. Amryt competes with other pharmaceutical companies focused on rare diseases, such as Albireo Pharma (ALBO), but differentiates itself through its specific product portfolio and development pipeline. The industry is also influenced by factors such as patent expirations, pricing pressures, and the increasing cost of drug development.

Who Are AMYT's Key Customers?

• Patients with rare and orphan diseases, such as lipodystrophy, acromegaly, and Homozygous familial Hypercholesterolaemia.
• Hospitals and clinics that treat these patients.
• Specialty pharmacies that dispense the company's products.

How Amryt Pharma plc Is Valued

Relative to its peer group, AMYT's quantitative score of 58/100 is roughly in line with the peer average of 51/100.

Company Profile

Amryt Pharma plc operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Dublin, IE. The company is led by CEO Joseph A. Wiley. AMYT has traded publicly since 2020.

ROE -9%Key Financial Metrics

Return on equity for Amryt Pharma plc stands at -9.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.3%, showing how much profit it generates from its asset base. A current ratio of 1.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Amryt Pharma plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

AMYT Financials

AMYT Latest News

No recent news available for AMYT.

AMYT Analyst Consensus

AMYT MoonshotScore

What Investors Ask About Amryt Pharma plc (AMYT) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources